KR102631920B1 - A food composition comprising Neomysis awatschensis oil for anti-obesity - Google Patents
A food composition comprising Neomysis awatschensis oil for anti-obesity Download PDFInfo
- Publication number
- KR102631920B1 KR102631920B1 KR1020210057667A KR20210057667A KR102631920B1 KR 102631920 B1 KR102631920 B1 KR 102631920B1 KR 1020210057667 A KR1020210057667 A KR 1020210057667A KR 20210057667 A KR20210057667 A KR 20210057667A KR 102631920 B1 KR102631920 B1 KR 102631920B1
- Authority
- KR
- South Korea
- Prior art keywords
- oil
- obesity
- weight
- group
- insect
- Prior art date
Links
- 230000003579 anti-obesity Effects 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title abstract description 42
- 235000013305 food Nutrition 0.000 title abstract description 26
- 241001380753 Neomysis awatschensis Species 0.000 title description 4
- 241000238631 Hexapoda Species 0.000 claims abstract description 30
- 235000019480 chamomile oil Nutrition 0.000 claims abstract description 6
- 239000010628 chamomile oil Substances 0.000 claims abstract description 6
- 239000003921 oil Substances 0.000 claims description 73
- 235000019198 oils Nutrition 0.000 claims description 73
- 238000010171 animal model Methods 0.000 claims description 17
- 208000008589 Obesity Diseases 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 235000020824 obesity Nutrition 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 210000000577 adipose tissue Anatomy 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 8
- 201000010063 epididymitis Diseases 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 102000016267 Leptin Human genes 0.000 claims description 7
- 108010092277 Leptin Proteins 0.000 claims description 7
- 229940039781 leptin Drugs 0.000 claims description 7
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 7
- 210000004185 liver Anatomy 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 230000004580 weight loss Effects 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 239000004615 ingredient Substances 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 15
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 14
- 241000593508 Garcinia Species 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 241000237858 Gastropoda Species 0.000 description 11
- 235000009200 high fat diet Nutrition 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 230000003442 weekly effect Effects 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 108010010234 HDL Lipoproteins Proteins 0.000 description 7
- 102000015779 HDL Lipoproteins Human genes 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 235000013402 health food Nutrition 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 4
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 241000245665 Taraxacum Species 0.000 description 4
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 4
- 235000003484 annual ragweed Nutrition 0.000 description 4
- 235000006263 bur ragweed Nutrition 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 235000003488 common ragweed Nutrition 0.000 description 4
- 235000018823 dietary intake Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000009736 ragweed Nutrition 0.000 description 4
- 244000119461 Garcinia xanthochymus Species 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 238000011888 autopsy Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 239000001149 (9Z,12Z)-octadeca-9,12-dienoate Substances 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 244000042664 Matricaria chamomilla Species 0.000 description 2
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 238000004159 blood analysis Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- ZAZKJZBWRNNLDS-UHFFFAOYSA-N methyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC ZAZKJZBWRNNLDS-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 235000021049 nutrient content Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- WTTJVINHCBCLGX-UHFFFAOYSA-N (9trans,12cis)-methyl linoleate Natural products CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 description 1
- DVWSXZIHSUZZKJ-UHFFFAOYSA-N 18:3n-3 Natural products CCC=CCC=CCC=CCCCCCCCC(=O)OC DVWSXZIHSUZZKJ-UHFFFAOYSA-N 0.000 description 1
- LNJCGNRKWOHFFV-UHFFFAOYSA-N 3-(2-hydroxyethylsulfanyl)propanenitrile Chemical compound OCCSCCC#N LNJCGNRKWOHFFV-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- -1 Cis-11,14-eicosadienoic acid methyl ester Chemical class 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 241000173371 Garcinia indica Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- XSXIVVZCUAHUJO-UHFFFAOYSA-N Homo-gamma-linoleic acid Natural products CCCCCC=CCC=CCCCCCCCCCC(O)=O XSXIVVZCUAHUJO-UHFFFAOYSA-N 0.000 description 1
- 241001495448 Impatiens <genus> Species 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- PKIXXJPMNDDDOS-UHFFFAOYSA-N Methyl linoleate Natural products CCCCC=CCCC=CCCCCCCCC(=O)OC PKIXXJPMNDDDOS-UHFFFAOYSA-N 0.000 description 1
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047295 Ventricular hypertrophy Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- 239000001071 citrus reticulata blanco var. mandarin Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000002816 gill Anatomy 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229930190166 impatien Natural products 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- DVWSXZIHSUZZKJ-YSTUJMKBSA-N methyl linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(=O)OC DVWSXZIHSUZZKJ-YSTUJMKBSA-N 0.000 description 1
- IZFGRAGOVZCUFB-HJWRWDBZSA-N methyl palmitoleate Chemical compound CCCCCC\C=C/CCCCCCCC(=O)OC IZFGRAGOVZCUFB-HJWRWDBZSA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000000551 statistical hypothesis test Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/02—Other edible oils or fats, e.g. shortenings, cooking oils characterised by the production or working-up
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/40—Shell-fish
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
- A23V2250/2042—Marine animal, fish extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/34—Membrane process
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/50—Concentrating, enriching or enhancing in functional factors
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
곤쟁이의 신규 용도로서 항비만을 위한 식품 조성물로 활용하는 방안이 제시된다. 본 발명은 곤쟁이 오일을 포함하는 항비만용 식품 조성물을 제공한다.As a new use of the insect, a method of using it as a food composition for anti-obesity is proposed. The present invention provides a food composition for anti-obesity containing chamomile oil.
Description
본 발명은 항비만용 식품 조성물에 관한 것으로, 보다 상세하게는 곤쟁이 오일을 포함하는 항비만용 식품 조성물에 관한 것이다.The present invention relates to a food composition for anti-obesity, and more specifically, to a food composition for anti-obesity containing dandelion oil.
경제발전과 더불어 우리나라 생활방식은 서구 선진국 형태로 발전함에 따라 식생활의 변화 및 육체적인 활동이 감소되면서, 신체 내의 체지방이 증가되고 대사의 불균형으로 비만 인구가 증가하고 있으며, 이로 인해 당뇨병, 고지혈증, 혈전장애 등 심혈관계 질환이 복합적으로 나타나는 이른바 대사증후군의 발생빈도가 지속적으로 높아 지고 있다(Lee SJ, Park JY, Nam CM, Jee SH. 2008. The prevalence estimation of metabolic syndrome and it's related factors based on data from general health medical examination: a multi-center study. J Korean Soc Health Information Health Statistics 33: 119-133; Frohlich J, Lear SA. 2002. Old and new risk factors for atherosclerosis and development of treatment recommendations. Clin Exp Pharmacol Physiol 29: 838-842).Along with economic development, our country's lifestyle has developed into that of advanced Western countries. As dietary habits change and physical activity decreases, body fat in the body increases and the number of obese people increases due to metabolic imbalance, resulting in diabetes, hyperlipidemia, and blood clots. The incidence of the so-called metabolic syndrome, which is a combination of cardiovascular diseases such as disability, is continuously increasing (Lee SJ, Park JY, Nam CM, Jee SH. 2008. The prevalence estimation of metabolic syndrome and it's related factors based on data from general health medical examination: a multi-center study. J Korean Soc Health Information Health Statistics 33: 119-133; Frohlich J, Lear SA. 2002. Old and new risk factors for atherosclerosis and development of treatment recommendations. Clin Exp Pharmacol Physiol 29 : 838-842).
비만은 한 가지 원인으로 발생하는 질병이 아니라, 유전적, 환경적, 사회적 요인들에 의해 복합적으로 나타나는 증후군으로, 에너지의 과다 섭취 후 체내 대사활동에서 소비되지 못하고 지방조직에 중성지방으로 축적되어 발 생된다(Chua, S.C.Jr. Monogenic models of obesity. Behav Genet. 27: 277-284, 1997). 또한, 비만에서 보이 는 혈중 지방산(fatty acid) 농도와 복부 비만의 증가는 고지혈증과 제 2형 당뇨병의 흔한 증상으로, 자유지방 산의 증가는 심실 비대를 야기하고(DeFronzo, R.A, Ferrannini, E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 14(3): 173-194, 1991), 복부 지방 축적은 인슐린 저항성의 유발에 밀접한 연관성이 있음이 보고되었고(Tamori, Y., Kasuga, M. Obesity and insulin resistance. Nippon Rinsho. 67(2):236-244, 2009), 이로 인하여 고혈압, 동맥경화증, 당뇨병, 고지혈증 등의 생활습관병을 야기하는 원인이 되거나 건강을 악화시키는 요인이 되고 있다.Obesity is not a disease caused by a single cause, but a syndrome that is caused by a combination of genetic, environmental, and social factors. After excessive intake of energy, it is not consumed in the body's metabolic activities and is accumulated as neutral fat in adipose tissue. (Chua, S.C.Jr. Monogenic models of obesity. Behav Genet. 27: 277-284, 1997). In addition, increased blood fatty acid concentration and abdominal obesity seen in obesity are common symptoms of hyperlipidemia and type 2 diabetes, and increased free fatty acid causes ventricular hypertrophy (DeFronzo, R.A, Ferrannini, E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 14(3): 173-194, 1991), abdominal fat accumulation is closely related to causing insulin resistance. It has been reported (Tamori, Y., Kasuga, M. Obesity and insulin resistance. Nippon Rinsho. 67(2):236-244, 2009), which causes lifestyle diseases such as hypertension, arteriosclerosis, diabetes, and hyperlipidemia. This is becoming a factor that worsens health.
곤쟁이(Neomysis awatschensis)는 곤쟁이과에 속하는 갑각류로, 대부분 바다에 서식하며 작은 새우처럼 생겼다. 몸길이는 1 내지 2 cm 정도이고, 여덟 쌍의 가슴다리가 있고 가슴다리의 기부에 노출된 아가미를 가진 점이 새우와 다르다. 한국 서해에서 많이 잡히는데, 소금에 절인 것을 곤쟁이젓이라 하여 먹으며, 많이 잡히는 곳에서는 사료 및 거름으로도 쓰인다. 우리나라 연안에 서식하는 20여 종의 곤쟁이는 몸길이 약 1 cm이며 '자하(紫蝦)'라고도 한다.Neomysis awatschensis (Neomysis awatschensis) is a crustacean belonging to the Awatsidae family. It lives mostly in the sea and looks like a small shrimp. The body length is about 1 to 2 cm, and it differs from shrimp in that it has eight pairs of pectoral legs and has gills exposed at the base of the pectoral legs. It is caught in large quantities in the West Sea of Korea, and when pickled in salt, it is eaten as gonjaengijeot, and in places where it is caught in large quantities, it is also used as feed and fertilizer. There are about 20 species of gophers that live along the coast of Korea, with a body length of about 1 cm, and are also called 'jaha (紫蝦)'.
그러나 아직까지 곤쟁이를 항비만을 위한 식품 조성물에 활용하고자 하는 사례는 보고되지 않고 있다.However, there have been no reported cases of using bugs in food compositions for anti-obesity yet.
본 발명에서는 곤쟁이의 신규 용도로서 항비만을 위한 식품 조성물로 활용하는 방안을 제시하고자 한다.In the present invention, we would like to propose a new use of gnats as a food composition for anti-obesity.
상기 과제를 해결하기 위한 일 양태로서 본 발명은, 곤쟁이 오일을 포함하는 항비만용 식품 조성물을 제공한다.As an aspect for solving the above problems, the present invention provides a food composition for anti-obesity containing insect oil.
또한 상기 곤쟁이 오일은 인지질 함량이 60 내지 70 중량%인 것을 특징으로 하는 항비만용 식품 조성물을 제공한다.In addition, the insect oil provides a food composition for anti-obesity, characterized in that the phospholipid content is 60 to 70% by weight.
상기 과제를 해결하기 위한 다른 양태로서 본 발명은, (a) 건조된 곤쟁이에 90 내지 100 %(v/v)의 주정을 10 내지 20배수 투입하여 추출하는 단계; (b) 상기 (a) 단계의 추출물을 1차 여과 후 40 내지 60℃에서 1차 감압농축하는 단계; 및 (c) 상기 (b) 단계의 농축물을 2차 여과 후 50 내지 100℃에서 2차 감압농축하여 점도 700 내지 1,000 cPs의 오일을 제조하는 단계;를 포함하는 항비만용 곤쟁이 오일 제조방법을 제공한다.As another aspect for solving the above problem, the present invention includes the steps of (a) adding 10 to 20 times 90 to 100% (v/v) of alcohol to dried ragweed and extracting it; (b) first filtering the extract of step (a) and then first concentrating it under reduced pressure at 40 to 60°C; and (c) secondary filtration of the concentrate from step (b) and secondary concentration under reduced pressure at 50 to 100°C to produce oil with a viscosity of 700 to 1,000 cPs. to provide.
본 발명에 따르면, 곤쟁이를 이용한 식품 조성물의 신규 용도로서 곤쟁이 오일을 포함하는 항비만용 식품 조성물과, 곤쟁이의 항비만 효능 극대화를 위한 곤쟁이 오일을 제조하는 방법을 제공할 수 있다.According to the present invention, it is possible to provide an anti-obesity food composition containing chamomile oil as a new use of a food composition using chamomile, and a method for producing chamomile oil to maximize the anti-obesity effect of chamomile.
도 1에 본 발명의 시험예에서 곤쟁이 원물(a), 열풍건조물(b), 추출물(c), 1차 농축물(d), 2차 농축물(e) 및 곤쟁이 오일(f)을 나타낸 사진이다.
도 2는 동물시험에 사용된 시험물질로서 (a) 곤쟁이 오일 및 (b) 가르시니아를 나타낸 사진이다.
도 3은 곤쟁이 오일이 고지방식이에 의한 비만 동물모델의 주간 체중에 미치는 영향을 분석한 결과를 나타낸 그래프이다.
도 4는 곤쟁이 오일이 고지방식이에 의한 비만 동물모델의 주간 식이 및 음수 섭취량에 미치는 영향을 분석한 결과를 나타낸 그래프이다.
도 5는 곤쟁이 오일이 비만 동물모델의 조직 중량에 미치는 영향을 분석한 결과를 나타낸 그래프이다.
도 6은 곤쟁이 오일이 비만 동물모델의 T-Chol, TG, LDL, HDL 농도에 미치는 영향을 분석한 결과를 나타낸 그래프이다.
도 7은 곤쟁이 오일이 비만 동물모델의 혈청 Leptin 농도에 미치는 영향을 분석한 결과를 나타낸 그래프이다.Figure 1 is a photograph showing the raw material (a), hot air dried product (b), extract (c), primary concentrate (d), secondary concentrate (e), and insect oil (f) in the test example of the present invention. am.
Figure 2 is a photograph showing (a) insect oil and (b) garcinia as test substances used in animal testing.
Figure 3 is a graph showing the results of analyzing the effect of bug oil on the weekly body weight of an obese animal model caused by a high-fat diet.
Figure 4 is a graph showing the results of analyzing the effects of python oil on the weekly diet and water intake of an obese animal model caused by a high-fat diet.
Figure 5 is a graph showing the results of analyzing the effect of ragweed oil on the tissue weight of an obese animal model.
Figure 6 is a graph showing the results of analyzing the effect of ragweed oil on the concentrations of T-Chol, TG, LDL, and HDL in an obese animal model.
Figure 7 is a graph showing the results of analysis of the effect of bug oil on serum leptin concentration in an obese animal model.
이하 바람직한 실시예를 통하여 본 발명을 상세히 설명하기로 한다. 이에 앞서, 본 명세서 및 청구범위에 사용된 용어나 단어는 통상적이거나 사전적인 의미로 한정해서 해석되어서는 아니 되며, 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여, 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다. 따라서, 본 명세서에 기재된 실시예의 구성은 본 발명의 가장 바람직한 일실시예에 불과할 뿐이고 본 발명의 기술적 사상을 모두 대변하는 것은 아니므로, 본 출원시점에 있어서 이들을 대체할 수 있는 다양한 균등물과 변형예들이 있을 수 있음을 이해하여야 한다. 또한, 명세서 전체에서, 어떤 부분이 어떤 구성요소를 "포함"한다고 할 때, 이는 특별히 반대되는 기재가 없는 한, 다른 구성요소를 제외하는 것이 아니라 다른 구성요소를 더 포함할 수 있음을 의미한다.Hereinafter, the present invention will be described in detail through preferred embodiments. Prior to this, the terms or words used in this specification and claims should not be construed as limited to their usual or dictionary meanings, and the inventor should appropriately define the concept of terms in order to explain his or her invention in the best way. Based on the principle of definability, it must be interpreted with meaning and concept consistent with the technical idea of the present invention. Therefore, the configuration of the embodiments described in this specification is only one of the most preferred embodiments of the present invention and does not represent the entire technical idea of the present invention, so various equivalents and modifications can be substituted for them at the time of filing the present application. You must understand that there may be. Additionally, throughout the specification, when a part is said to “include” a certain element, this means that, unless specifically stated to the contrary, it does not exclude other elements but may further include other elements.
본 발명에서는 곤쟁이 오일의 동물시험에서 체중 감소, 간 지방 조직 및 부고환 지방 중량 감소, 혈중 콜레스테롤, LDL 및 HDL 함량 감소의 유의한 결과를 확인하였다. 따라서, 본 발명은 곤쟁이 오일을 포함하는 항비만용 식품 조성물을 개시한다.In the present invention, significant results of weight loss, reduction in liver adipose tissue and epididymal fat, and reduction in blood cholesterol, LDL, and HDL contents were confirmed in animal tests of snail oil. Accordingly, the present invention discloses a food composition for anti-obesity containing chamomile oil.
본 발명에서 상기 지표와 관련된 항비만 효능 증대를 위해 곤쟁이 오일은 (a)추출 단계, (b) 1차 여과 및 농축 단계 및 (c) 2차 여과 및 농축 단계를 거쳐 제조된다.In the present invention, in order to increase the anti-obesity efficacy related to the above indicators, python oil is prepared through (a) extraction step, (b) primary filtration and concentration step, and (c) secondary filtration and concentration step.
상기 (a) 단계에서 추출 용매로 주정을 사용 시 항비만 효능 증대에 가장 효과적인 것으로 확인되었으며, 건조된 곤쟁이에 90 내지 100 %(v/v)의 주정을 10 내지 20배수 투입하여 추출하는 것이 바람직하다. 또한 (b) 단계에서는 (a) 단계의 추출물을 1차 여과 후 1차 감압농축하되 40 내지 60℃에서 수행되는 것이 바람직하고, (c) 단계에서는 농축된 추출물을 2차 여과 후 2차 감압농축하되, 50 내지 100℃에서 점도가 700 내지 1,000 cPs 수준이 될 때까지 농축하여 오일을 제조함으로써 항비만 효능을 극대화시킬 수 있게 된다.It was confirmed that the use of alcohol as an extraction solvent in step (a) was most effective in increasing anti-obesity efficacy, and it is preferable to extract by adding 10 to 20 times 90 to 100% (v/v) of alcohol to dried insects. do. In addition, in step (b), the extract from step (a) is first filtered and then first concentrated under reduced pressure, preferably at 40 to 60°C, and in step (c), the concentrated extract is second filtered and then second concentrated under reduced pressure. However, the anti-obesity effect can be maximized by producing the oil by concentrating it at 50 to 100°C until the viscosity reaches the level of 700 to 1,000 cPs.
본 발명에 따른 조성물은 식품 조성물의 형태로 제공되며, 예컨대, 기능성 식품(functional food), 영양 보조제(nutritional supplement), 건강식품(health food), 식품 첨가제(food additives) 등의 형태를 포함할 수 있다. 상기 유형의 식품 조성물은 당 업계에 공지된 통상적인 방법에 따라 다양한 형태로 제조할 수 있다.The composition according to the present invention is provided in the form of a food composition and may include, for example, the form of functional food, nutritional supplement, health food, food additives, etc. there is. Food compositions of this type can be prepared in various forms according to conventional methods known in the art.
예를 들면, 건강 식품으로는 상기 조성물 자체를 차, 주스 또는 드링크의 형태로 제조하여 음용하도록 하거나, 과립화, 캡슐화 또는 분말화하여 섭취할 수 있다. 또한 기능성 식품으로는 음료(알콜성 음료 포함), 과실 및 그의 가공식품(예: 과일통조림, 병조림, 잼, 마말레이드 등), 어류, 육류 및 그 가공식품(예: 햄, 소시지 콘비프 등), 빵류 및 면류(예: 우동, 메밀국수, 라면, 스파게티, 마카로니 등), 과즙, 각종 드링크, 쿠키, 엿, 유제품(예: 버터, 치즈 등), 식용식물유지, 마아가린, 식물성 단백질, 레토르트 식품, 냉동식품, 각종 조미료(예: 된장, 간장, 소스 등) 등에 추출물을 첨가하여 제조할 수 있다. 또한 본 발명의 조성물을 식품 첨가제의 형태로 사용하기 위해서는 분말 또는 농축액 형태로 제조하여 사용할 수 있다.For example, as a health food, the composition itself can be prepared and consumed in the form of tea, juice, or drink, or can be consumed by granulating, encapsulating, or powdering. In addition, functional foods include beverages (including alcoholic beverages), fruits and their processed foods (e.g. canned fruit, bottled foods, jam, marmalade, etc.), fish, meat and their processed foods (e.g. ham, sausages, corned beef, etc.), and breads. and noodles (e.g. udon, buckwheat noodles, ramen, spaghetti, macaroni, etc.), fruit juice, various drinks, cookies, taffy, dairy products (e.g. butter, cheese, etc.), edible vegetable oil, margarine, vegetable protein, retort food, frozen. It can be manufactured by adding extracts to food, various seasonings (e.g. soybean paste, soy sauce, sauce, etc.). Additionally, in order to use the composition of the present invention in the form of a food additive, it can be prepared and used in the form of a powder or concentrate.
본 발명에 따른 식품 조성물 중 상기 추출물 또는 오일의 바람직한 함량은 식품 조성물 총 중량에 대하여 0.001 내지 50%일 수 있으며, 바람직하게는 0.1 내지 10% 범위로 함유될 수 있다.The preferred content of the extract or oil in the food composition according to the present invention may be 0.001 to 50%, preferably 0.1 to 10%, based on the total weight of the food composition.
이하, 구체적인 실시예를 들어 본 발명을 보다 상세히 설명한다.Hereinafter, the present invention will be described in more detail through specific examples.
곤쟁이 오일 제조Mandarin oil production
하기 표 1의 영양성분으로 구성된 냉동 곤쟁이 생물(원물)(개체 크기 약 1 cm) 30 kg을 상온에서 해동 및 24시간 열풍건조(50℃ 8시간, 70℃ 8시간 및 80℃ 8시간)하여 하기 표 2의 영양성분으로 구성된 곤쟁이 열풍건조 건물(수율 13%)을 준비하였다. 이후, 곤쟁이 건물에 95 %(v/v) 주정을 15 배수로 투입하고 1시간 동안 추출하였다. 이후, 곤쟁이 추출물을 여과 필터로 1차 여과한 후 50℃에서 1차 감압농축하고, 다시 여과 필터로 2차 여과한 후 50 내지 100℃에서 점도가 800 내지 900 cPs가 될 때까지 2차 감압농축하여 곤쟁이 오일을 회수하였다. 도 1에 상기 과정에서 곤쟁이 원물(a), 열풍건조물(b), 추출물(c), 1차 농축물(d), 2차 농축물(e) 및 곤쟁이 오일(f)을 나타내었고, 곤쟁이 오일의 성분 및 품질 분석 결과를 하기 표 3에 나타내었다.30 kg of frozen insect organisms (raw material) (individual size about 1 cm) consisting of the nutrients shown in Table 1 below were thawed at room temperature and dried with hot air for 24 hours (50°C for 8 hours, 70°C for 8 hours, and 80°C for 8 hours). We prepared hot-air dried dried insects (yield 13%) consisting of the nutrients shown in Table 2. Afterwards, 15 times 95% (v/v) alcohol was added to the dried bean sprouts and extracted for 1 hour. Afterwards, the insect extract was first filtered using a filtration filter, first concentrated under reduced pressure at 50°C, secondly filtered again with a filter, and then secondarily concentrated under reduced pressure at 50 to 100°C until the viscosity reached 800 to 900 cPs. In this way, the insect oil was recovered. Figure 1 shows the raw material (a), hot air dried material (b), extract (c), primary concentrate (d), secondary concentrate (e), and insect oil (f) in the above process. The ingredients and quality analysis results are shown in Table 3 below.
시험방법Test Methods
(1) 시험물질의 조제(1) Preparation of test substances
본 시험에 사용된 시험물질을 하기 표 4에 정리하였고, 물질 사진을 도 2에 나타내었다.The test substances used in this test are summarized in Table 4 below, and a photo of the substances is shown in Figure 2.
(도 2(a))public sample
(Figure 2(a))
(도 2(b))positive sample
(Figure 2(b))
시험물질은 실험에 사용하기 전 100% 발효 주정으로 먼저 곤쟁이 오일을 용하한다음 corn oil을 넣어 교반기를 이용하였으며, 최종 volume은 D.W를 이용하여 시료를 제작하였다. 각 시료의 농도별 희석은 D.W로 하였으며 제조된 시료는 냉장 보관하였다.Before using the test substance in the experiment, 100% fermented alcohol was first dissolved in 100% fermented alcohol, then corn oil was added and a stirrer was used. The final volume was prepared using D.W. Each sample was diluted by concentration using D.W, and the prepared sample was stored in a refrigerator.
(2) 실험동물 및 사육환경(2) Experimental animals and breeding environment
사육기간 중 온도는 23±1℃, 습도 50±5%, 소음 60 phone 이하, 조명시간 07:00-19:00(1일 12시간), 조도 150-300 lux, 환기는 시간당 10-12회의 환경을 유지하였다. 동물 입수 시 모든 동물의 일반 건강상태에 대한 수의학적 검역을 실시하며, 시험을 실시하는데 적합하도록 설치류용 일반사료(Samtoko, Gyeonggi, Korea)와 필터 및 자외선 살균기로 여과 살균된 정제수를 자유롭게 섭취하도록 하였다. 본 실험은 주식회사 인비보의 동물실험윤리규정을 준수하여 수행하였다(승인번호 IV-RA-04-2006-26).During the breeding period, the temperature is 23±1℃, humidity 50±5%, noise less than 60 phones, lighting hours 07:00-19:00 (12 hours a day), illuminance 150-300 lux, ventilation 10-12 times per hour. The environment was maintained. Upon receipt of animals, veterinary quarantine was conducted to check the general health of all animals, and they were allowed to freely consume general rodent feed (Samtoko, Gyeonggi, Korea) and purified water that had been filtered and sterilized with a filter and ultraviolet sterilizer to be suitable for conducting tests. . This experiment was conducted in compliance with the Animal Experiment Ethics Regulations of Invivo Co., Ltd. (Approval No. IV-RA-04-2006-26).
(3) 실험군 구성(3) Composition of experimental group
순화기간이 끝난 후 고지방식이와 곤쟁이 오일을 6주간 투여하며 비만을 유도 및 비만 억제를 확인하였다. 실험군은 정상군(Normal group), 대조군(비만유도군, Control group), 농도별 시험군(고지방식이와 곤쟁이 오일 시험물질, 저농도(NA 10 mg/kg), 고농도(NA 30 mg/kg)로 투여한 실험군), 양성대조군(고지방식이와 가르시니아 시험물질 200 mg/kg)으로 나누어 군당 10마리씩 설정하였다. 실험식이의 경우 정상군은 일반식이(샘타코, 한국)를 급여하고, 비만유도모델은 Rodent Diet with 60%Kcal Fat(새론바이오, 한국)를 급여하였다. After the acclimatization period was over, high-fat diet and beetle oil were administered for 6 weeks, and obesity was induced and obesity suppressed. The experimental group was the normal group, the control group (obesity-induced group), and the test group by concentration (high-fat diet and insect oil test substance, low concentration (NA 10 mg/kg), high concentration (NA 30 mg/kg). The animals were divided into a positive control group (high-fat diet and 200 mg/kg of Garcinia test substance) and a positive control group (10 animals per group). In the case of the experimental diet, the normal group was fed a regular diet (Sam Taco, Korea), and the obesity-induced model was fed a Rodent Diet with 60%Kcal Fat (Saeron Bio, Korea).
(4) 주간 바이오마커 분석 및 부검(4) Weekly biomarker analysis and autopsy
주간 체중변화는 주 1회 일정시간에 모든 실험군의 개체별 체중을 측정하고, 식이 섭취량은 급여 후 익일 잔량을 측정하여 주 1회 측정하였다. 부검은 호흡 마취 후 채혈하여 혈액 분석에 사용하고, 간(Liver)과 부고환지방(Epididymal fat)을 적출하여 무게를 측정하였다.Weekly weight change was measured by measuring the weight of each individual in all experimental groups at a certain time once a week, and dietary intake was measured once a week by measuring the remaining amount the day after feeding. For the autopsy, blood was collected after respiratory anesthesia and used for blood analysis, and the liver and epididymal fat were extracted and weighed.
(5) 혈액 분석(5) Blood analysis
동물 부검 시 복대정맥에서 채혈하고 30분 동안 응고 과정을 거친 후 원심분리기로 10분 동안 3,000 rpm으로 원심 분리하여 혈청을 회수하였다. 회수한 혈청을 TC(Total cholesterol), TG(Triglyceride), HDL-C(high density lipoprotein cholesterol) 및 LDL-C(Low density lipoprotein cholesterol) 분석에 사용, 녹십자 의료재단(GC Labs, 한국)에 분석을 의뢰하였고, 혈중 leptin 함량은 ELISA kit(ab199082; Abcam)를 이용하여 분석하였다.At the time of animal autopsy, blood was collected from the abdominal vena cava, coagulated for 30 minutes, and then centrifuged at 3,000 rpm for 10 minutes to recover serum. The recovered serum was used for analysis of TC (Total cholesterol), TG (Triglyceride), HDL-C (high density lipoprotein cholesterol), and LDL-C (Low density lipoprotein cholesterol), and was analyzed by the Green Cross Medical Foundation (GC Labs, Korea). The request was made, and the leptin content in the blood was analyzed using an ELISA kit (ab199082; Abcam).
(6) 통계 분석(6) Statistical analysis
각 군 간의 통계적 유의성 검정에 따른 통계분석은 ANOVA(one-way analysis of variance test) Duncan 사후검정 비교를 실시하여 p<0.05일 때 유의한 것으로 판정하였다(SPSS V12., SPSS Inc, Chicago, IL, USA).Statistical analysis according to the statistical significance test between each group was performed using ANOVA (one-way analysis of variance test) and Duncan's post hoc test comparison, and p < 0.05 was judged to be significant (SPSS V12., SPSS Inc, Chicago, IL, USA).
시험결과Test result
(1) 주간 체중 및 식이음수 섭취량 변화(1) Changes in weekly weight and dietary water intake
도 3은 곤쟁이 오일이 고지방식이에 의한 비만 동물모델의 주간 체중에 미치는 영향을 분석한 결과를 나타낸 그래프이다. Figure 3 is a graph showing the results of analyzing the effect of bug oil on the weekly body weight of an obese animal model caused by a high-fat diet.
도 3을 참조하면, 곤쟁이 오일이 고지방식이로 유도된 비만 동물모델에서의 체중 증가에 대한 효과를 조사하기 위해 고지방 식이 공급과 함께 농도별 곤쟁이 오일을 경구투여 하여 6주간 비만을 유도하며 체중을 조사한 결과, 실험 4주차에서부터 각 실험군별 체중의 차이가 유의적으로 차이를 보였으며, 정상군(Normal)이 25.62±0.28 g, 대조군(Control)이 28.29±0.74 g으로 대조군이 정상군에 비해 유의적으로 높게 나타났으며, 곤쟁이 오일 저농도(NO10)는 26.65±1.18 g, 곤쟁이 오일 고농도(NO30)는 27.70±0.96 g, 실험대조군(Garcinia)은 28.50±0.76 g로 대조군과 비교하여 저농도, 고농도 투여군 순으로 체중증가율이 감소하였다. 실험 종료 시점인 6주차 기준으로 정상군(Normal)은 26.95±0.28 g, 대조군(Control)은 34.01±0.74 g으로 정상군과 비교시 체중증가율이 유의적인 차이를 보였고, 곤쟁이 오일 저농도(NO10)는 30.06±1.18 g, 곤쟁이 오일 고농도(NO30)는 32.15±0.96 g, 실험대조군(Garcinia)은 32.71±0.76 g로 곤쟁이 오일 저농도, 고농도 투여군 순으로 체중이 낮은 것으로 확인되었다.Referring to FIG. 3, in order to investigate the effect of snail oil on weight gain in an obese animal model induced by a high-fat diet, snail oil of various concentrations was orally administered along with a high-fat diet to induce obesity for 6 weeks and increase body weight. As a result of the investigation, there was a significant difference in body weight between each experimental group from the 4th week of the experiment, with the Normal group being 25.62±0.28 g and the Control group being 28.29±0.74 g, which was significant compared to the normal group. It was found to be relatively high, with the low concentration of impatiens oil (NO10) being 26.65±1.18 g, the high concentration of impregnation oil (NO30) being 27.70±0.96 g, and the experimental control group (Garcinia) being 28.50±0.76 g. Compared to the control group, the low and high concentration administration groups were In that order, the weight gain rate decreased. At the end of the experiment, at week 6, the normal group (Normal) was 26.95 ± 0.28 g and the control group (Control) was 34.01 ± 0.74 g, showing a significant difference in weight gain rate compared to the normal group, and the low concentration of bee oil (NO10) was Body weight was confirmed to be lower in that order: 30.06 ± 1.18 g, high concentration of benign oil (NO30) was 32.15 ± 0.96 g, and 32.71 ± 0.76 g for the experimental control group (Garcinia).
(2) 주간 식이 및 음수 섭취량(2) Weekly dietary and water intake
도 4는 곤쟁이 오일이 고지방식이에 의한 비만 동물모델의 주간 식이 및 음수 섭취량에 미치는 영향을 분석한 결과를 나타낸 그래프이다. 도 4에서 A는 식이 섭취량, B는 음수 섭취량을 나타낸다.Figure 4 is a graph showing the results of analyzing the effects of python oil on the weekly diet and water intake of an obese animal model caused by a high-fat diet. In Figure 4, A represents dietary intake and B represents drinking water intake.
도 4를 참조하면, 비만 유도동물에서 곤쟁이 오일이 주간섭취량과 음수섭취량에 미치는 영향을 확인하기 위해 각 군간 식이 음수 섭취량을 측정한 결과, 각 실험군의 식이섭취량은 6주차를 기준으로 정상군(Normal)이 3.35±0.12 g로 나타났으며, 대조군(Control)은 1.86±0.16 g, 곤쟁이 오일 저농도(10 mg/kg, NO10)는 1.97±0.17 g, 곤쟁이 오일 고농도(30 mg/kg, NO30)는 1.87±0.19 g, 실험대조군(Garcinia)은 1.97±0.15 g으로 나타났다. 또한 6주차 기준 음수섭취량은 정상군(Normal)은 4.11±0.10 g, 대조군(Control)은 2.15±0.17 g, 곤쟁이 오일 저농도(10 mg/kg, NO10)는 2.59±0.29 g, 곤쟁이 오일 고농도(30 mg/kg, NO30)는 2.40±0.35 g, 실험대조군(Garcinia)은 2.46±0.44 g으로 조사되었다. 시험기간 중 식이섭취량과 음수섭취량은 고지방식이를 섭취하는 대조군과 실험군에 비해 일반 식이를 섭취하는 정상군이 비교적 높은 양상을 보였으나, 실험군 간에는 차이를 보이지 않았다.Referring to FIG. 4, as a result of measuring dietary water intake between each group to confirm the effect of snail oil on the weekly intake and water intake in obesity-induced animals, the dietary intake of each experimental group was normal based on the 6th week. ) was found to be 3.35 ± 0.12 g, the control group was 1.86 ± 0.16 g, the low concentration of gopher oil (10 mg/kg, NO10) was 1.97 ± 0.17 g, and the high concentration of gonorrhea oil (30 mg/kg, NO30) was 1.97 ± 0.17 g. It was 1.87±0.19 g, and the experimental control group (Garcinia) was 1.97±0.15 g. In addition, the drinking water intake as of week 6 was 4.11 ± 0.10 g for the Normal group, 2.15 ± 0.17 g for the Control group, 2.59 ± 0.29 g for low-concentration benix oil (10 mg/kg, NO10), and 2.59 ± 0.29 g for high-concentration benix oil (30 mg/kg, NO10). mg/kg, NO30) was found to be 2.40±0.35 g, and the experimental control group (Garcinia) was found to be 2.46±0.44 g. During the test period, dietary intake and water intake were relatively higher in the normal group consuming a normal diet compared to the control group and experimental group consuming a high-fat diet, but there was no difference between the experimental groups.
(3) 조직 중량(3) Tissue weight
도 5는 곤쟁이 오일이 비만 동물모델의 조직 중량에 미치는 영향을 분석한 결과를 나타낸 그래프이다. 도 5에서 A는 간 중량, B는 부고환 지방 중량을 나타낸다.Figure 5 is a graph showing the results of analyzing the effect of bug oil on the tissue weight of an obese animal model. In Figure 5, A represents the liver weight and B represents the epididymal fat weight.
도 5를 참조하면, 비만 동물모델에서 곤쟁이 오일을 농도별로 투여했을 때 간 지방 조직 중량과 부고환 지방 중량에 미치는 영향을 분석한 결과, 비만 동물모델의 조직 중량에 미치는 영향을 확인한 시험 중 먼저 간 조직의 중량을 측정한 시험에서 정상군(Normal)은 1.11±0.02 g, 대조군(Control)은 1.15±0.03 g으로 대조군이 정상군에 비해 간 조직의 중량이 증가하는 경향을 보이는 것으로 확인되었다. 반면, 곤쟁이 오일 저농도(10 mg/kg, NO10) 실험군은 1.00±0.02 g, 곤쟁이 오일 고농도(30 mg/kg, NO30) 실험군은 1.03±0.03 g, 실험대조군(Garcinia)은 1.06±0.02 g으로 나타나, 모든 실험군에서 대조군과 유의적인 차이를 보였다. 특히, 곤쟁이 오일 저농도, 고농도 수준으로 감소되는 것으로 나타났다.Referring to FIG. 5, as a result of analyzing the effect on liver adipose tissue weight and epididymal fat weight when administered at different concentrations in an obese animal model, liver tissue was first tested to determine the effect on the tissue weight of an obese animal model. In a test measuring the weight, the normal group (Normal) was 1.11 ± 0.02 g and the control group (Control) was 1.15 ± 0.03 g, and it was confirmed that the control group showed a tendency to increase the weight of liver tissue compared to the normal group. On the other hand, the experimental group with low concentration of insect oil (10 mg/kg, NO10) showed 1.00±0.02 g, the experimental group with high concentration of insect oil (30 mg/kg, NO30) showed 1.03±0.03 g, and the experimental control group (Garcinia) showed 1.06±0.02 g. , All experimental groups showed significant differences from the control group. In particular, it was found to be reduced at low and high concentrations of gopher oil.
부고환 지방 조직의 경우 정상군(Normal)이 0.32±0.02 g으로 대조군(Control)의 1.79±0.13 g과 비교하여 대조군이 유의하게 증가되었다. 실험군별로는 곤쟁이 오일 저농도(10 mg/kg, NO10) 실험군은 1.36±0.13 g, 곤쟁이 오일 고농도(30 mg/kg, NO30) 실험군은 1.52±0.07 g, 실험대조군(Garcinia)은 1.76±0.13 g으로, 곤쟁이 오일 저농도, 고농도 순으로 부고환 지방 조직의 무게가 감소된 것으로 확인되었다.In the case of epididymal fat tissue, the normal group (Normal) was 0.32 ± 0.02 g, which was significantly increased compared to the control group (1.79 ± 0.13 g). By experimental group, the experimental group with low concentration of insect oil (10 mg/kg, NO10) was 1.36±0.13 g, the experimental group with high concentration of insect oil (30 mg/kg, NO30) was 1.52±0.07 g, and the experimental control group (Garcinia) was 1.76±0.13 g. It was confirmed that the weight of epididymal adipose tissue was reduced in the order of low and high concentrations of insect oil.
(4) 일반 혈액학적 분석(4) General hematological analysis
도 6은 곤쟁이 오일이 비만 동물모델의 T-Chol, TG, LDL, HDL 농도에 미치는 영향을 분석한 결과를 나타낸 그래프이다.Figure 6 is a graph showing the results of analyzing the effect of ragweed oil on the concentrations of T-Chol, TG, LDL, and HDL in an obese animal model.
도 6을 참조하면, 비만 동물모델에서 곤쟁이 오일이 혈중 T-Chol(Total cholesterol), TG(Triglyceride), LDL(Low-density lipoprotein) 및 HDL(High-density lipoprotein) 농도에 미치는 영향을 확인하기 위하여 측정한 결과, 혈중 총 콜레스테롤의 함량은 정상군(Normal)의 경우 114.63±2.28 mg/dL로 대조군의 202.88±9.99 mg/dL보다 유의적인 차이를 보였으며, 곤쟁이 오일 고농도(30 mg/kg, NO30) 실험군이 207.50±7.30 mg/dL, 실험대조군(Garcinia)이 208.63±12.73 mg/dL로 대조군과 비슷한 경향을 보였으나, 곤쟁이 오일 저농도(10 mg/kg, NO10) 실험군은 177.88±8.55 mg/dL로 대조군에 비해 감소하는 경향을 보였다.Referring to Figure 6, in order to confirm the effect of dandelion oil on blood T-Chol (Total cholesterol), TG (Triglyceride), LDL (Low-density lipoprotein), and HDL (High-density lipoprotein) concentrations in an obese animal model. As a result of the measurement, the total cholesterol content in the blood was 114.63 ± 2.28 mg/dL in the normal group, which was significantly different from 202.88 ± 9.99 mg/dL in the control group. ) The experimental group showed a similar tendency to the control group at 207.50±7.30 mg/dL and the experimental control group (Garcinia) at 208.63±12.73 mg/dL, but the low concentration of benign oil (10 mg/kg, NO10) experimental group showed 177.88±8.55 mg/dL. showed a tendency to decrease compared to the control group.
혈중 LDL cholesterol을 측정한 결과, 정상군(Normal)이 9.89±0.35 mg/dL, 대조군(Control)이 36.29±1.83 mg/dL로 유의적인 차이를 보였다. 실험군별로는 곤쟁이 오일 저농도(10 mg/kg, NO10) 실험군이 26.80±2.25 mg/dL, 곤쟁이 오일 고농도(30 mg/kg, NO30) 실험군이 32.00±1.76 mg/dL, 실험대조군(Garcinia) 실험군이 34.21±2.06 mg/dL로 나타나, 대조군과 비교하여 곤쟁이 오일을 투여한 실험군에서 저농도 투여군에서 혈중 LDL 함량이 유의적으로 낮게 감소하는 것으로 확인되었다. As a result of measuring LDL cholesterol in the blood, there was a significant difference between the Normal group (9.89 ± 0.35 mg/dL) and the Control group (36.29 ± 1.83 mg/dL). By experimental group, the low-concentration insect oil (10 mg/kg, NO10) experimental group was 26.80±2.25 mg/dL, the high-concentration insect oil (30 mg/kg, NO30) experimental group was 32.00±1.76 mg/dL, and the control group (Garcinia) experimental group was 34.21. It was found to be ±2.06 mg/dL, and compared to the control group, it was confirmed that the blood LDL content was significantly reduced in the low concentration group in the experimental group administered dandelion oil.
혈중 TG(Triglyceride)를 측정한 결과, 정상군의 185.50±24.23 mg/dL에 비해 대조군은 292.13±9.39 mg/dL로 유의적인 차이를 보였으며, 곤쟁이 오일 저농도(10 mg/kg, NO10) 실험군이 273.88±3.89 mg/dL, 곤쟁이 오일 고농도(30 mg/kg, NO30) 실험군이 281.63±8.70 mg/dL, 실험대조군(Garcinia) 실험군이 285.88±4.52 mg/dL로, 대조군과 비교하여 실험군간 유의적인 차이는 나타나지 않았다.As a result of measuring TG (Triglyceride) in the blood, the control group showed a significant difference of 292.13 ± 9.39 mg/dL compared to the normal group's 185.50 ± 24.23 mg/dL, and the low-concentration benign oil (10 mg/kg, NO10) experimental group showed a significant difference. 273.88±3.89 mg/dL, 281.63±8.70 mg/dL in the high-concentration bean oil (30 mg/kg, NO30) experimental group, and 285.88±4.52 mg/dL in the experimental control (Garcinia) experimental group. There was a significant difference between the experimental groups compared to the control group. No difference appeared.
혈중 HDL cholesterol을 측정한 결과, 정상군(Normal)이 103.93±2.46 mg/dL, 대조군(Control)이 159.45±6.34 mg/dL로 나타났고, 실험군별로는 곤쟁이 오일 저농도(10 mg/kg, NO10) 실험군이 146.10±5.42 mg/dL, 곤쟁이 오일 고농도(30 mg/kg, NO30) 실험군이 172.81±5.60 mg/dL, 실험대조군(Garcinia) 실험군이 170.45±10.24 mg/dL로 나타나, 대조군과 비교하여 곤쟁이 오일을 저농도로 투여한 실험군이 낮은 경향을 보였다.As a result of measuring HDL cholesterol in the blood, the normal group (Normal) was found to be 103.93 ± 2.46 mg/dL and the control group (Control) was 159.45 ± 6.34 mg/dL. By experimental group, the low-concentration benign oil (10 mg/kg, NO10) experimental group This was 146.10±5.42 mg/dL, the high-concentration garcinia oil (30 mg/kg, NO30) experimental group was 172.81±5.60 mg/dL, and the experimental control group (Garcinia) was 170.45±10.24 mg/dL, compared to the control group. The experimental group administered at a low concentration tended to have lower levels.
(5) 사이토카인 분석(5) Cytokine analysis
도 7은 곤쟁이 오일이 비만 동물모델의 혈청 Leptin 농도에 미치는 영향을 분석한 결과를 나타낸 그래프이다.Figure 7 is a graph showing the results of analysis of the effect of bug oil on serum leptin concentration in an obese animal model.
지방조직에서 생산되는 Obese(Ob) 유전자의 사이토카인으로 식욕을 억제하고 포만감을 느끼게 하는 호로몬으로 식욕과 에너지 대사를 조절한다. 비만인 경우 leptin의 분비량이 증가하는 것으로 알려져 있어 체지방량을 나타내는 지표로 비만연구에 많이 사용되어진다. 도 7을 참조하면, 비만 동물모델에서 곤쟁이 오일의 항비만 효과를 확인하기 위하여 혈청 Leptin의 양을 측정하여 분석한 결과, 정상군(Normal)의 경우 535.3±108.8 pg/ml로 대조군의 5088.7±476.8 pg/ml보다 유의하게 낮았다. 반면, 곤쟁이 오일 저농도(10 mg/kg, NO10) 실험군은 3629.9±624.8 pg/ml, 곤쟁이 오일 고농도(30 mg/kg, NO30) 실험군은 4043.7±525.4 pg/ml, 실험대조군(Garcinia)은 5176.8±406.6 pg/ml로 조사되어, 대조군(Control)군에 비해 곤쟁이 오일을 투여한 실험군에서 혈중 leptin의 농도가 감소하는 경향을 보이거나 유의하게 감소된 것으로 확인되었다.It is a cytokine of the Obese (Ob) gene produced in adipose tissue and is a hormone that suppresses appetite and causes a feeling of fullness. It regulates appetite and energy metabolism. It is known that leptin secretion increases in the case of obesity, so it is often used in obesity research as an indicator of body fat mass. Referring to Figure 7, the amount of serum leptin was measured and analyzed to confirm the anti-obesity effect of gnatia oil in an obese animal model. As a result, the amount was 535.3 ± 108.8 pg/ml in the normal group, compared to 5088.7 ± 476.8 in the control group. It was significantly lower than pg/ml. On the other hand, the experimental group with low concentration of insect oil (10 mg/kg, NO10) was 3629.9±624.8 pg/ml, the experimental group with high concentration of insect oil (30 mg/kg, NO30) was 4043.7±525.4 pg/ml, and the experimental control group (Garcinia) was 5176.8±. It was found to be 406.6 pg/ml, and it was confirmed that the concentration of leptin in the blood tended to decrease or was significantly decreased in the experimental group administered dandelion oil compared to the control group.
이와 같이, 곤쟁이 오일은 체중 감소, 간 지방 조직 및 부고환 지방 중량 감소, 혈중 콜레스테롤, LDL 및 HDL 함량 감소의 유의한 결과로부터 항비만 효능이 우수한 것으로 확인되었다.In this way, it has been confirmed that gnatia oil has excellent anti-obesity efficacy, with significant results in weight loss, reduction in liver adipose tissue and epididymal fat weight, and reduction in blood cholesterol, LDL, and HDL contents.
이하에서는 본 발명에 따른 곤쟁이 오일을 포함하는 항비만용 식품 조성물의 적용 제조예를 설명하나, 이에 한정되는 것은 아니다.Hereinafter, a manufacturing example of the application of the anti-obesity food composition containing the insect oil according to the present invention will be described, but it is not limited thereto.
제조예 1: 산제 제조Preparation Example 1: Powder preparation
하기 표 5에서는 상술한 본 발명에 따른 곤쟁이 오일을 포함하는 항비만용 식품 조성물의 산제 조성을 예시하고 있다. 산제는 하기 성분들을 혼합하고 기밀포에 충진하여 제조될 수 있다.Table 5 below illustrates the powder composition of the anti-obesity food composition containing the insect oil according to the present invention described above. Powder can be prepared by mixing the following ingredients and filling them in an airtight bubble.
제조예 2: 정제 제조Preparation Example 2: Tablet Preparation
하기 표 6에서는 상술한 본 발명에 따른 곤쟁이 오일을 포함하는 항비만용 식품 조성물의 정제 조성을 예시하고 있다. 정제는 하기 성분들을 혼합한 후 통상의 정제 제조방법에 따라 타정하여 제조될 수 있다.Table 6 below illustrates the tablet composition of the anti-obesity food composition containing the insect oil according to the present invention described above. Tablets can be manufactured by mixing the following ingredients and compressing them according to a conventional tablet manufacturing method.
제조예 3: 캅셀제 제조Preparation Example 3: Capsule preparation
하기 표 7에서는 상술한 본 발명에 따른 곤쟁이 오일을 포함하는 항비만용 식품 조성물의 캅셀제 조성을 예시하고 있다. 캅셀제는 통상의 캅셀제 제조방법에 따라 하기 성분들을 혼합하고 젤라틴 캡슐에 충전하여 제조될 수 있다.Table 7 below illustrates the capsule composition of the anti-obesity food composition containing the insect oil according to the present invention described above. Capsules can be manufactured by mixing the following ingredients and filling them into gelatin capsules according to a typical capsule manufacturing method.
제조예 4: 액제 제조Preparation Example 4: Liquid preparation
하기 표 8에서는 상술한 본 발명에 따른 곤쟁이 오일을 포함하는 항비만용 식품 조성물의 액제 조성을 예시하고 있다. 액제는 통상의 액제 제조방법에 따라 정제수에 각각의 하기 성분들을 가하여 용해시키고 레몬향을 적량 가한 후 하기 성분들을 혼합한 다음 정제수를 가하여 전체 100 ㎖로 조절한 후 갈색병에 충진 및 멸균시켜 제조될 수 있다.Table 8 below illustrates the liquid composition of the anti-obesity food composition containing the insect oil according to the present invention described above. The liquid can be prepared by adding and dissolving each of the following ingredients in purified water according to a typical liquid preparation method, adding an appropriate amount of lemon flavor, mixing the following ingredients, adding purified water to adjust the total to 100 ml, and then filling and sterilizing it in a brown bottle. You can.
제조예 5: 건강 식품 제조Preparation Example 5: Preparation of health food
하기 표 9에서는 상술한 본 발명에 따른 곤쟁이 오일을 포함하는 항비만용 식품 조성물의 기능성 건강 식품 조성을 나타내고 있다. 하기 조성에서 비타민 및 미네랄 혼합물의 조성비는 비교적 건강 식품에 적합한 성분을 바람직한 제제예로 혼합 조성한 것을 나타내고 있으나, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강 식품 제조방법에 따라 각 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강 식품 조성물 제조에 사용할 수 있다.Table 9 below shows the functional health food composition of the anti-obesity food composition containing the insect oil according to the present invention described above. In the composition below, the composition ratio of the vitamin and mineral mixture represents a mixture of ingredients relatively suitable for health food as a preferred preparation example, but the mixing ratio may be modified arbitrarily, and each component is mixed according to a typical health food manufacturing method. Then, granules can be prepared and used to prepare health food compositions according to conventional methods.
제조예 6: 건강 음료 제조Preparation Example 6: Preparation of health drink
하기 표 10에서는 상술한 본 발명에 따른 곤쟁이 오일을 포함하는 항비만용 식품 조성물의 기능성 건강 음료 조성을 나타내고 있다. 건강 음료 제조는 통상의 건강 음료 제조방법에 따라 예컨대, 하기 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 ℓ 용기에 취득하여 밀봉 멸균한 후 냉장 보관하여 사용할 수 있다. 하기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였으나, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Table 10 below shows the functional health drink composition of the anti-obesity food composition containing the insect oil according to the present invention described above. The production of a health drink follows a typical health drink production method, for example, mixing the following ingredients, stirring and heating at 85°C for about 1 hour, filtering the resulting solution, placing it in a sterilized 2 liter container, sealing and sterilizing it. It can be stored refrigerated and used. The following composition ratio is a mixture of ingredients that are relatively suitable for beverages of choice as a preferred example, but the mixing ratio may be arbitrarily modified depending on regional and ethnic preferences such as demand class, demand country, and usage purpose.
이상에서 설명한 본 발명의 바람직한 실시예들은 기술적 과제를 해결하기 위해 개시된 것으로, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자라면 본 발명의 사상 및 범위 안에서 다양한 수정, 변경, 부가 등이 가능할 것이며, 이러한 수정 변경 등은 이하의 특허청구범위에 속하는 것으로 보아야 할 것이다.The preferred embodiments of the present invention described above were disclosed to solve technical problems, and those skilled in the art will be able to make various modifications, changes, additions, etc. within the spirit and scope of the present invention. , such modifications and changes should be regarded as falling within the scope of the patent claims below.
Claims (3)
(b) 상기 (a) 단계의 추출물을 1차 여과 후 40 내지 60℃에서 1차 감압농축하는 단계; 및
(c) 상기 (b) 단계의 농축물을 2차 여과 후 50 내지 100℃에서 2차 감압농축하여 점도 700 내지 1,000 cPs의 오일을 제조하는 단계;
를 포함하는 항비만용 곤쟁이 오일 제조방법으로서,
상기 곤쟁이 오일은 비만 유도 동물모델에서 체중 감소, 간 지방 조직 및 부고환 지방 중량 감소 및 혈중 렙틴(Leptin) 농도 감소를 통해 확인된 항비만 효능을 나타내는 유효성분이고,
상기 곤쟁이 오일의 인지질 함량은 60 내지 70 중량%인 것을 특징으로 하는 항비만용 곤쟁이 오일 제조방법.(a) extracting 90 to 100% (v/v) alcohol by adding 10 to 20 times the amount of alcohol to the dried insect;
(b) first filtering the extract of step (a) and then first concentrating it under reduced pressure at 40 to 60°C; and
(c) secondary filtration of the concentrate from step (b) and secondary concentration under reduced pressure at 50 to 100°C to produce an oil with a viscosity of 700 to 1,000 cPs;
As a method for producing anti-obesity insect oil comprising,
The bug oil is an active ingredient that exhibits anti-obesity efficacy confirmed through weight loss, reduction in liver adipose tissue and epididymal fat weight, and reduction in blood leptin concentration in an obesity-inducing animal model,
A method for producing anti-obesity chamomile oil, characterized in that the phospholipid content of the chamomile oil is 60 to 70% by weight.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210057667A KR102631920B1 (en) | 2021-05-04 | 2021-05-04 | A food composition comprising Neomysis awatschensis oil for anti-obesity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210057667A KR102631920B1 (en) | 2021-05-04 | 2021-05-04 | A food composition comprising Neomysis awatschensis oil for anti-obesity |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220150551A KR20220150551A (en) | 2022-11-11 |
KR102631920B1 true KR102631920B1 (en) | 2024-01-31 |
Family
ID=84042628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210057667A KR102631920B1 (en) | 2021-05-04 | 2021-05-04 | A food composition comprising Neomysis awatschensis oil for anti-obesity |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102631920B1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102222043B1 (en) * | 2020-08-07 | 2021-03-04 | 주식회사 동원에프앤비 | Method of krill oil preparation and composition of krill oil |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021045554A1 (en) * | 2019-09-05 | 2021-03-11 | 장영진 | Pharmaceutical composition comprising processed fish product and/or processed soybean product as active ingredient |
-
2021
- 2021-05-04 KR KR1020210057667A patent/KR102631920B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102222043B1 (en) * | 2020-08-07 | 2021-03-04 | 주식회사 동원에프앤비 | Method of krill oil preparation and composition of krill oil |
Also Published As
Publication number | Publication date |
---|---|
KR20220150551A (en) | 2022-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
World Health Organization et al. | Keep fit for life: meeting the nutritional needs of older persons | |
CN102178086B (en) | Feed additive for improving quality and flavor of pork, feed, and preparation method thereof | |
CN101632655A (en) | Resveratrol and bioflavonoid nutritional composition for delaying senility | |
JP2008174539A (en) | Healthy and functional food for obesity patient using purple-colored potato | |
KR101791206B1 (en) | The onion juice and method of it | |
KR20190003304A (en) | Composition for preventing, improving or treating fatty liver disease comprising Gryllus bimaculatus extract as effective component | |
US8663725B2 (en) | Method for deriving a high-protein powder/ omega 3 oil and double distilled water from any kind of fish or animal ( protein) | |
KR100747481B1 (en) | Cracker and method for producing thereof | |
Kurve et al. | The effect of feeding native warm season grasses in the stocker phase on the carcass quality, meat quality, and sensory attributes of beef loin steaks from grain-finished steers | |
CN111972494A (en) | Sports nutritional milk powder and preparation method thereof | |
KR102631920B1 (en) | A food composition comprising Neomysis awatschensis oil for anti-obesity | |
Kim et al. | Influence of supplemental Schisandra chinensis powder on growth performance, serum cholesterol, and meat quality of broilers | |
Kumar et al. | Selected fruit pomaces: nutritional profile, health benefits, and applications in functional foods and feeds | |
Sanwo et al. | Meat quality and lipid profile of broiler chickens fed diets containing turmeric (Curcuma longa) powder and cayenne pepper (Capsicum frutescens) powder as antioxidants | |
CN114532503B (en) | Red apple and cherry plum composition and application thereof in reducing blood fat | |
Mahmoud et al. | Egyptian “Ful Medames” Mitigates Metabolic Syndrome-Associated Inflammation through Regulation of Resistin, Leptin and Adipokine mRNA Expression in Wistar Rats | |
KR101165933B1 (en) | Feed composition for pig breeding comprising cinnammons | |
KR20210014272A (en) | Functional beverage composition for companion animal | |
KR20200120549A (en) | Oral composition for reducing body weight or body fat comprising Artemisia dracunculus and Taraxacum officinale | |
KR101038716B1 (en) | Boiled fish paste made from Misgurnus mizolepis | |
JP2000253851A (en) | Highly functional food | |
CN107396970A (en) | A kind of production method of the Yoghourt rich in chlorella promotion growth factor | |
JPH08242812A (en) | Functional food | |
KR101038715B1 (en) | Boiled fish paste made from Misgurnus mizolepis | |
TW200417366A (en) | Remedy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right |